GFM
COGT icon

GF Fund Management’s Cogent Biosciences COGT Stock Holding History

GF Fund Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$133K Sell
3,435
-12
-0.3% -$420 ﹤0.01% 307
2026
Q1 		$133K Buy
3,447
+431
+14% +$15.9K ﹤0.01% 313
2025
Q4 		$107K Buy
3,016
+10
+0.3% +$281 ﹤0.01% 340
2025
Q3 		$43.2K Buy
3,006
+178
+6% +$2.11K ﹤0.01% 411
2025
Q2 		$20.3K Hold
2,828
– – ﹤0.01% 502
2025
Q1 		$16.9K Buy
2,828
+509
+22% +$3.99K ﹤0.01% 518
2024
Q4 		$18.1K Buy
+2,319
New +$23.1K ﹤0.01% 483

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GF Fund Management's COGT Position: Q2 2026 in Review

GF Fund Management reduced its Cogent Biosciences (COGT) stake by 0.35% in Q2 2026, selling an estimated $420 and leaving 3,435 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #307.

GF Fund Management first reported a position in COGT in Q4 2024 and has held it in 7 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • GF Fund Management held 3,435 shares of Cogent Biosciences worth $133K as of Q2 2026.
  • GF Fund Management sold 12 Cogent Biosciences shares in Q2 2026, an estimated $420.
  • Cogent Biosciences made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #307 holding.
  • GF Fund Management first reported a position in Cogent Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.